§ Claim under review · Mixed
"High serum levels of ergothioneine, found only in mushrooms, reduced dementia risk (Alzheimer's and non-Alzheimer's) by about 75%" plus caption: "Even if there was a low vegetable intake, it didn't matter as long as ergothioneine is high. Very underrated anti-aging / anti-inflammatory molecule."
Verdict
Source exists but framing is misleading
Confidence
MediumSummary
There is a real study behind this post. Researchers followed 1,344 Japanese adults aged 65 and over for about 11 years and found that people with higher blood levels of ergothioneine, a compound most abundant in mushrooms, developed dementia less often, including both Alzheimer's and non-Alzheimer's types. But the post overstates it in several ways. This was an observational study, meaning it found an association, not proof that ergothioneine causes lower dementia risk. The specific "75 percent" figure does not appear in the study's published summary and could not be verified. Ergothioneine is not found only in mushrooms; liver, kidney, black and red beans, and oat bran also contain it. Most importantly, the study found the ergothioneine link held in both low and high vegetable eaters, which is a statistical result about independence, not evidence that you can skip vegetables. No clinical trial has yet shown that taking ergothioneine supplements prevents dementia, and several of the study's authors work for a beverage company with a commercial interest in the compound.
The readings
key figures from the evidenceHisayama Study cohort size, age 65+
median follow-up duration in the study
participants who developed all-cause dementia
Why this verdict
Evidence
A real, recent, peer-reviewed study underlies this post. In a prospective longitudinal analysis of the Hisayama Study, 1344 Japanese community residents aged 65 and over without dementia at baseline were followed for a median of 11.2 years, from 2012 to 2023, with serum ergothioneine measured by liquid chromatography mass spectrometry and divided into quartiles . During follow-up 273 participants developed all-cause dementia, of whom 201 had Alzheimer's disease and 72 had non-Alzheimer's dementia, and the age and sex adjusted hazard ratios for all three outcomes decreased progressively across increasing quartiles of serum ergothioneine, with all P values for trend below 0.05 .
On the vegetable question, the paper addressed this directly in two ways. The associations remained significant after adjustment for a wide range of cardiovascular, lifestyle, and dietary factors including daily vegetable intake, and in subgroup analyses stratified by daily vegetable intake, higher serum ergothioneine was consistently associated with lower dementia risk irrespective of vegetable consumption .
The authors' own conclusion is stated in conditional terms. They concluded that higher serum ergothioneine levels were associated with a lower risk of developing all-cause dementia, Alzheimer's disease, and non-Alzheimer's dementia, and that since ergothioneine cannot be synthesized in the human body, a diet rich in ergothioneine may be beneficial in reducing dementia risk .
METHODOLOGY AND CONTEXT
Design: Prospective observational cohort. Not a trial. No intervention, no randomization, no ergothioneine administered.
Population: 1344 Japanese community residents aged 65 and over, dementia-free at baseline . Narrow demographic. Findings do not automatically transfer to younger or non-Japanese populations with different dietary patterns.
Statistical adjustment: Three models were used: model 1 adjusted for age and sex; model 2 added low education, systolic blood pressure, antihypertensive medication, diabetes, total cholesterol, BMI, ECG abnormalities, stroke history, smoking, alcohol, and exercise; model 3 added daily vegetable intake . This is a reasonably thorough adjustment set for a nutritional epidemiology paper.
The chart in the post: The axes described in the image, log of serum ergothioneine on the x-axis against hazard ratio on a doubling scale, correspond to the paper's figure of restricted cubic splines for the association between serum ergothioneine levels and risk of all-cause dementia . A spline curve shows a continuous dose-response shape with confidence bands that widen substantially at the extremes where few participants sit. The y-axis extending down to 0.0625 is a strong indication that the curve's lower tail carries very wide uncertainty. Reading a single headline percentage off the far end of a spline is not the same as the study's primary quartile result.
Funding and conflict of interest: Four of the twelve authors are affiliated with the Research Institute, Suntory Global Innovation Center Ltd. , a commercial entity with a direct interest in ergothioneine as an ingredient. This does not invalidate the work, but it is material context the post omits.
Ergothioneine food sources: Analysis of common foods found that only some foods contain ergothioneine, with the highest concentrations detected in specialty mushrooms, kidney, liver, black and red beans, and oat bran . Mushrooms contain the highest levels, especially king oyster, maitake, oyster, shiitake, and porcini, while other ergothioneine-rich foods include liver, black beans, red beans, and oat bran , and it is produced by certain types of bacteria and fungi .
Supporting evidence elsewhere: The direction of association is not unique to this cohort. A Singapore study of 470 elderly subjects attending memory clinics examined whether ergothioneine status could predict subsequent cognitive and functional decline, noting that prior associations with cognitive impairment and cerebrovascular disease had come from cross-sectional studies . All of this remains observational.
Findings
✓ What's accurate 5
- A real, peer-reviewed, primary study exists and matches the post's chart type and outcome categories.
- The study did find lower dementia risk at higher ergothioneine quartiles, and it did break results into Alzheimer's and non-Alzheimer's dementia . The post correctly names both subtypes.
- The association did hold across vegetable intake strata . The post's underlying observation about the stratified analysis is real.
- The cohort size and median follow-up of 11.2 years are substantial for a nutritional biomarker study . This is not a weak study.
- Mushrooms genuinely are the dominant dietary source.
≈ What's misleading 7
- **Unsupported causal inference.** The post says ergothioneine "reduced" dementia risk. This is an observational cohort measuring an association. The authors themselves wrote only that a diet rich in ergothioneine "may be beneficial." Serum ergothioneine plausibly tracks overall diet quality, absorption capacity, gut health, and general vigor, any of which could drive the association independently.
- **Fabricated or unverifiable magnitude.** I could not locate any "75%" figure in the abstract, results summary, or conclusions. The published summary reports only a progressive decrease across quartiles with P for trend below 0.05. It does not headline a 75 percent reduction. A 75 percent reduction corresponds to a hazard ratio of 0.25, which on the post's own chart sits deep in the low-precision tail of the spline. Treat this number as unsupported until the full results table is checked.
- **Factual error on sourcing.** "Found only in mushrooms" is wrong. Kidney, liver, black and red beans, and oat bran also contain meaningful amounts , and the compound is made by various bacteria and fungi , not mushrooms exclusively.
- **Inverted logic on vegetables.** This is the most serious distortion. Finding that an association holds within both low and high vegetable subgroups means the ergothioneine signal is statistically independent of vegetable intake. It does not mean vegetables provide no benefit, and it certainly does not mean ergothioneine substitutes for them. The study did not test whether skipping vegetables while having high ergothioneine produces equivalent outcomes. Saying vegetables "didn't matter" converts a statistical independence finding into a dietary instruction the data cannot support.
- **Marketing framing.** "Anti-aging" is not a study endpoint. The paper measured incident dementia, not aging. The post attaches a supplement newsletter call to action, which reframes an observational biomarker finding as a purchase rationale.
- **Omitted qualifier: no trial evidence for supplementation.** The study measured naturally occurring serum levels. It says nothing about whether taking an ergothioneine capsule lowers dementia risk. As the Alzheimer's Drug Discovery Foundation summarizes, blood levels tend to decrease with age especially in people with physical or cognitive decline, but clinical trials have not yet been conducted to determine whether supplementation can prevent or reverse these declines . Preclinical studies suggest antioxidant and anti-inflammatory protection at the cell level , which is mechanistic, not outcome evidence.
- **Omitted industry involvement.** Multiple authors work for Suntory's research institute , unmentioned in the post.
? What's uncertain 4
- **The exact quartile hazard ratios and confidence intervals.** I retrieved the abstract, methods, and conclusions but not the full results table. I therefore cannot state the precise effect size, confirm whether the top-quartile estimate approaches 0.25, or report the confidence interval widths. My search budget was exhausted before this was resolved. This is the single largest gap in this report.
- **Whether "75%" originates from a specific number in the paper, from a subgroup, from the age-and-sex-adjusted model only rather than the fully adjusted model, or from eyeballing the spline curve.** All are plausible; I cannot distinguish them.
- **Reverse causation.** An 11.2 year median follow-up reduces but does not eliminate the possibility that early, undiagnosed neurodegeneration lowers ergothioneine levels rather than the reverse.
- **Generalizability** beyond older Japanese adults.
Sources
2 of 4 linked to records**Meng X, Ohara T, Nishioka K, et al. "Serum ergothioneine and risk of dementia in a general older Japanese population: the Hisayama Study." *Psychiatry and Clinical Neurosciences*, 2025;79(12):808-816.** Primary, peer-reviewed journal article. https://onlinelibrary.wiley.com/doi/10.1111/pcn.13893 and https://pmc.ncbi.nlm.nih.gov/articles/PMC12683611/
**Ergothioneine dietary source analysis, *Journal of Agricultural and Food Chemistry*.** Primary, peer-reviewed. https://pubs.acs.org/doi/10.1021/jf071328f
**Alzheimer's Drug Discovery Foundation, Cognitive Vitality rating on ergothioneine.** Secondary, expert non-profit review. https://www.alzdiscovery.org/cognitive-vitality/ratings/ergothioneine
**Cheah/Halliwell group, "Low Plasma Ergothioneine Predicts Cognitive and Functional Decline," *Antioxidants* 2022.** Primary, supporting cohort. https://pmc.ncbi.nlm.nih.gov/articles/PMC9495818/